Asuragen, a Bio-Techne brand

11/04/2024

Introducing the first multi-analyte, qPCR-based liquid biopsy assay for the detection of ESR1 mutations from plasma. Watch this short video to learn how the QuantideX® qPCR ESR1 exoMutation Kit unlocks the power of exosomes for advanced cancer mutation detection.

Unlock high-sensitivity ESR1 mutation testing with ExoRNA & ctDNA co-analysis via liquid biopsy. Detects the 11 most prevalent ESR1 variants in plasma.

08/04/2024

On , let's reaffirm our commitment to health as a human right & the importance of diversity in healthcare. By including more ethnicities in genetic databases & testing, we can address health disparities & ensure everyone receives the care they deserve.

The diversity of the US population is not represented in the gene panels most commonly used to screen for risk of cystic fibrosis. Addressing this gap should increase accuracy and improve access to care for millions.

03/04/2024

This , take the initiative to prioritize your family's health. Carrier screening can provide valuable insights into genetic risks, allowing families to make informed decisions about their health and future. Learn more: https://bit.ly/3sB0QYz

An updated guide on carrier screening for genetic conditions. Pan-ethnic carrier screening & insights into genetic data disparities across ethnicities.

02/04/2024

Did you know that Fragile X Syndrome is the leading known genetic cause of ? On , take a moment to learn more about the condition, as well as support & celebrate individuals and families affected by . 💙

Fragile X syndrome is the most common known cause of autism or autism spectrum disorders. Most people who have fragile X syndrome have not been diagnosed. Learn more about this syndrome and the resources that are available.

27/03/2024

Widely respected in the field of haematology, Dr Emilie Klein works in the Laboratoire d’Hématologie Cytogénétique at CHU de Bordeaux and has contributed to 18 pieces of published research. We can’t wait to see her present a poster at SFH 2024 next week. She’ll be sharing the results of a comparison between Asuragen’s QuantideX® qPCR BCR-ABL IS kit and an “in-house” technique for the quantification of BCR::ABL1 major transcripts.

26/03/2024

Asuragen's QuantideX qPCR BCR-ABL IS Kit has completed the Class C Certification under the new European Union In Vitro Diagnostic Regulation (IVDR)! The highly sensitive qPCR-based in vitro diagnostic test quantifies BCR-ABL1 and ABL1 transcripts in blood samples from patients with CML to determine their response to tyrosine kinase inhibitor (TKI) therapy. Learn more about the QuantideX qPCR BCR-ABL IS Kit here.

The QuantideX® qPCR BCR-ABL IS Kit is now compliant with the latest diagnostic regulations in Europe MINNEAPOLIS, March 22, 2024 /PRNewswire/ — Bio-Techne Corporation (NASDAQ: TECH) today announced that Asuragen, part of Bio-Techne’s Molecular Diagnostics Division, has completed the Class C Cer...